1. Academic Validation
  2. Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program

Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program

  • Pediatr Blood Cancer. 2012 Aug;59(2):329-32. doi: 10.1002/pbc.23319.
Malcolm A Smith 1 Richard Gorlick E Anders Kolb Richard Lock Hernan Carol John M Maris Stephen T Keir Christopher L Morton C Patrick Reynolds Min H Kang Janine Arts Tarig Bashir Michel Janicot Raushan T Kurmasheva Peter J Houghton
Affiliations

Affiliation

  • 1 Cancer Therapy Evaluation Program, NCI, Bethesda, Maryland, USA. Malcolm.Smith@nih.gov
Abstract

JNJ-26854165 was originally developed as an activator of p53 capable of inducing Apoptosis in Cancer cell lines. In vitro, JNJ-26854165 demonstrated cytotoxic activity. The ALL cell line panel had a significantly lower median IC(50) (0.85 µM) than the remaining cell lines. In vivo JNJ-26854165 induced significant differences in EFS distribution compared to control in 18 of 37 solid tumors and in 5 of 7 of the evaluable ALL xenografts. Objective responses were observed in 4 of 37 solid tumor xenografts, and 2 of 7 ALL xenografts achieved PR or CR. Responses were noted in xenografts with both mutant and wild-type p53.

Figures
Products